Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass

Antonio Ferreira, Ahmed Fahiem Abdelsalam Emara, David Herzig, Andreas Melmer, Andreas P Vogt, Christos T Nakas, Andrea Facchinetti, Chiara Dalla Man, Lia Bally, Antonio Ferreira, Ahmed Fahiem Abdelsalam Emara, David Herzig, Andreas Melmer, Andreas P Vogt, Christos T Nakas, Andrea Facchinetti, Chiara Dalla Man, Lia Bally

Abstract

Introduction: Postprandial hypoglycaemia after gastric bypass surgery (also known as postbariatric hypoglycaemia or PBH) is an increasingly encountered clinical problem. PBH is characterised by meal-induced rapid spikes and consequent falls in glycaemia, resulting in both hypoglycaemia burden and high glycaemic variability. Despite its frequency, there is currently no approved pharmacotherapy. The purpose of this investigation is to evaluate efficacy and safety of empagliflozin 25 mg, a sodium-glucose cotransporter 2-inhibitor, to reduce glucose excursions and hypoglycaemia burden in patients with PBH after gastric bypass surgery.

Methods and analysis: In a prospective, single-centre, randomised, double-blind, placebo-controlled, crossover trial, we plan to enrol 22 adults (≥18 years) with PBH after Roux-en-Y gastric bypass surgery (plasma or sensor glucose <3.0 mmol/L). Eligible patients will be randomised to receive empagliflozin 25 mg and placebo once daily, each for 20 days, in random order. Study periods will be separated by a 2-6 weeks wash-out period. The primary efficacy outcome will be the amplitude of plasma glucose excursion (peak to nadir) during a mixed meal tolerance test. Results will be presented as paired-differences±SD plus 95% CIs with p values and hypothesis testing for primary and secondary outcomes according to intention-to-treat. Secondary outcomes include continuous glucose monitoring-based outcomes, further metabolic measures and safety.

Ethics and dissemination: The DEEP-EMPA trial (original protocol title: Randomized, double-blind, placebo-controlled crossover trialassessing the impact of the SGLT2 inhibitor empagliflozin onpostprandial hypoglycaemia after gastric bypass) was approved by the Bern Ethics Committee (ID 2021-01187) and Swissmedic (Ref. Number: 102663190) in October and November 2021, respectively. First results are expected in the first quarter of 2023 and will be disseminated via peer-reviewed publications and presented at national and international conferences. The acronym DEEP was derived from an overarching project title (DEciphering the Enigma of Postprandial Hyperinsulinaemic Hypoglycaemia after Bariatric Surgery), the term EMPA stands for the drug empagliflozin.

Trial registration number: NCT05057819.

Keywords: General diabetes; General endocrinology; SURGERY.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
The DEEP-EMPA trial study design. CGM, continuous glucose monitoring; EOS, end of study visit; IMP, investigational medicinal product.

References

    1. Hofsø D, Fatima F, Borgeraas H, et al. . Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:912–24. 10.1016/S2213-8587(19)30344-4
    1. Angrisani L, Santonicola A, Iovino P, et al. . Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg 2017;27:2279–89. 10.1007/s11695-017-2666-x
    1. Lee CJ, Wood GC, Lazo M, et al. . Risk of post-gastric bypass surgery hypoglycemia in nondiabetic individuals: a single center experience. Obesity 2016;24:1342–8. 10.1002/oby.21479
    1. Halperin F, Patti ME, Skow M, et al. . Continuous glucose monitoring for evaluation of glycemic excursions after gastric bypass. J Obes 2011;2011:1–7. 10.1155/2011/869536
    1. Capristo E, Panunzi S, De Gaetano A, et al. . Incidence of hypoglycemia after gastric bypass vs sleeve gastrectomy: a randomized trial. J Clin Endocrinol Metab 2018;103:2136–46. 10.1210/jc.2017-01695
    1. Lazar LO, Sapojnikov S, Pines G, et al. . Symptomatic and asymptomatic hypoglycemia post three different bariatric procedures: a common and severe complication. Endocr Pract 2019. 10.4158/EP-2019-0185. [Epub ahead of print: 14 08 2019].
    1. Guarino D, Moriconi D, Mari A, et al. . Postprandial hypoglycaemia after Roux-en-Y gastric bypass in individuals with type 2 diabetes. Diabetologia 2019;62:178–86. 10.1007/s00125-018-4737-5
    1. Salehi M, Vella A, McLaughlin T, et al. . Hypoglycemia after gastric bypass surgery: current concepts and controversies. J Clin Endocrinol Metab 2018;103:2815–26. 10.1210/jc.2018-00528
    1. Craig CM, McLaughlin TL. Defining clinically important hypoglycemia in patients with postbariatric hypoglycemia. Surg Obes Relat Dis 2021;17:1865–72. 10.1016/j.soard.2021.06.013
    1. Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014;146:669–80. 10.1053/j.gastro.2013.11.044
    1. Salehi M, Gastaldelli A, D'Alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. J Clin Endocrinol Metab 2014;99:2008–17. 10.1210/jc.2013-2686
    1. Mulla CM, Goldfine AB, Dreyfuss JM, et al. . Plasma FGF-19 levels are increased in patients with Post-Bariatric hypoglycemia. Obes Surg 2019;29:2092–9. 10.1007/s11695-019-03845-0
    1. Abrahamsson N, Börjesson JL, Sundbom M, et al. . Gastric bypass reduces symptoms and hormonal responses in hypoglycemia. Diabetes 2016;65:2667–75. 10.2337/db16-0341
    1. van den Broek M, de Heide LJM, Sips FLP, et al. . Altered bile acid kinetics contribute to postprandial hypoglycaemia after Roux-en-Y gastric bypass surgery. Int J Obes 2021;45:619–30. 10.1038/s41366-020-00726-w
    1. Suhl E, Anderson-Haynes S-E, Mulla C, et al. . Medical nutrition therapy for post-bariatric hypoglycemia: practical insights. Surg Obes Relat Dis 2017;13:888–96. 10.1016/j.soard.2017.01.025
    1. Valderas JP, Ahuad J, Rubio L, et al. . Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg 2012;22:582–6. 10.1007/s11695-011-0581-0
    1. Hepprich M, Wiedemann SJ, Schelker BL, et al. . Postprandial hypoglycemia in patients after gastric bypass surgery is mediated by glucose-induced IL-1β. Cell Metab 2020;31:699–709. 10.1016/j.cmet.2020.02.013
    1. Tahrani AA, Barnett AH, Bailey CJ. Sglt inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140–51. 10.1016/S2213-8587(13)70050-0
    1. Kanai Y, Lee WS, You G, et al. . The human kidney low affinity Na+/glucose cotransporter SGLT2. delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397–404. 10.1172/JCI116972
    1. Seman L, Macha S, Nehmiz G, et al. . Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2013;2:152–61. 10.1002/cpdd.16
    1. Ferrannini E, Seman L, Seewaldt-Becker E, et al. . A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:721–8. 10.1111/dom.12081
    1. Merovci A, Solis-Herrera C, Daniele G, et al. . Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509–14. 10.1172/JCI70704
    1. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017;13:11–26. 10.1038/nrneph.2016.170
    1. Ferrannini E, Muscelli E, Frascerra S, et al. . Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499–508. 10.1172/JCI72227
    1. Zinman B, Wanner C, Lachin JM, et al. . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. 10.1056/NEJMoa1504720
    1. Wanner C, Inzucchi SE, Lachin JM, et al. . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34. 10.1056/NEJMoa1515920
    1. Fernandes NJ, Nguyen N, Chun E, et al. . Open-source algorithm to calculate mean amplitude of glycemic excursions using short and long moving averages. J Diabetes Sci Technol 2022;16:576–7. 10.1177/19322968211061165
    1. Scarpellini E, Arts J, Karamanolis G, et al. . International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol 2020;16:448–66. 10.1038/s41574-020-0357-5
    1. Schiavon M, Herzig D, Hepprich M, et al. . Model-based assessment of C-peptide secretion and kinetics in post gastric bypass individuals experiencing postprandial hyperinsulinemic hypoglycemia. Front Endocrinol 2021;12:611253. 10.3389/fendo.2021.611253
    1. Cobelli C, Dalla Man C, Toffolo G, et al. . The oral minimal model method. Diabetes 2014;63:1203–13. 10.2337/db13-1198
    1. International Hypoglycaemia Study Group . Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2017;40:155–7. 10.2337/dc16-2215
    1. Ferrannini E, Baldi S, Frascerra S, et al. . Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016;65:1190–5. 10.2337/db15-1356
    1. Harris PA, Taylor R, Minor BL, et al. . The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208. 10.1016/j.jbi.2019.103208
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi